Kolexia
Bazan Fernando Oncologie médicale
Bazan Fernando
Oncologie médicale
Le Mittan Annexe Du Hnfc
Montbéliard, France
111 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Tumeurs de l'ovaire Métastase tumorale Carcinomes Carcinome épithélial de l'ovaire Récidive tumorale locale Tumeurs de l'endomètre Tumeurs du sein triple-négatives Neutropénie

Collaborateurs

Voir plus
Chaigneau Loic
Chaigneau Loic
Le Mittan Annexe Du Hnfc, Montbéliard, France
Dobi Erion
Dobi Erion
Hôpital Jean-Minjoz, Besançon, France
Pivot Xavier
Pivot Xavier
Centre Paul Strauss, Strasbourg, France
Villanueva Cristian
Villanueva Cristian
Oncoclem, Saint-Jean-de-Védas, France

Industries

Voir plus
CanceroDigest
18 collaboration(s)
Dernière en 2023
Novartis
9 collaboration(s)
Dernière en 2023
Daiichi Sankyo
7 collaboration(s)
Dernière en 2023
AstraZeneca
5 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
VICTORIA: A Multicentric, Randomized, Non Comparative, Open-label Phase I/II Evaluating AZD2014 (Dual Mammalian Target of Rapamycin Complex 1/2 (mTORC1/mTORC2) Inhibitor) in Combination With Anastrozole Versus Anastrozole Alone in the Treatment of Metastatic Hormone Receptor-positive Endometrial Adenocarcinoma
Essai Clinique (Centre Léon-Bérard)   12 février 2024
IMMUNE CAPTURE: Immunomonitoring of Breast Cancer Patients During Systemic Treatment
Essai Clinique (Centre Georges-François Leclerc)   16 octobre 2023
LBA42 Olaparib vs placebo as maintenance therapy after platinum-based chemotherapy in advanced/metastatic endometrial cancer patients: The GINECO randomized phase IIb UTOLA trial
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
768P Preliminary results of an open-label, multicentric, phase Ib/II study to assess the safety and efficacy of AsiDNA, a DNA repair inhibitor, in addition to PARP inhibitor in patients with relapsed platinum sensitive ovarian cancer already treated with PARPi for at least 6 months (RevoCAN)
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
VolATIL: A Phase II Study Evaluating the Interest to Combine UCPVax a CD4 TH1-inducer Cancer Vaccine and Atezolizumab for the Treatment of Human PapillomaVirus Positive Cancers
Essai Clinique (CHU Besançon)   25 mai 2023
Ribosome biogenesis-based predictive biomarkers in endocrine therapy (Anastrozole) combined with mTOR inhibitor (Vistusertib) in endometrial cancer: translational study from the VICTORIA trial in collaboration with the GINECO group.
Molecular oncology   07 décembre 2022
Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumab.
Frontiers in cardiovascular medicine   23 septembre 2022
Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial.
European journal of cancer (Oxford, England : 1990)   05 septembre 2022
LBA17 Primary endpoint results of SYNERGY, a randomized phase II trial, first-line chemo-immunotherapy trial of durvalumab, paclitaxel, and carboplatin with or without the anti-CD73 antibody oleclumab in patients with advanced or metastatic triple-negative breast cancer (TNBC)
Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022   01 septembre 2022
PAOLA-1: Randomized, Double-Blind, Phase III Trial Olaparib vs. Placebo Patients With Advanced FIGO Stage IIIB-IV High Grade Serious or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer Treated Standard First-Line Treatment
Essai Clinique (Arcagy Research)   01 août 2022